Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Travere Therapeutics Inc (NASDAQ: TVTX) closed at $23.58 in the last session, up 1.07% from day before closing price of $23.33. In other words, the price has increased by $1.07 from its previous closing price. On the day, 1.32 million shares were traded.
Ratios:
We take a closer look at TVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.68 and its Current Ratio is at 1.71.
On October 21, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $9 to $27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 12 ’25 when ROTE WILLIAM E. sold 5,200 shares for $23.53 per share. The transaction valued at 122,356 led to the insider holds 98,519 shares of the business.
REED ELIZABETH E sold 8,000 shares of TVTX for $188,240 on Feb 12 ’25. The SVP, GC & CORPORATE SECRETARY now owns 89,482 shares after completing the transaction at $23.53 per share. On Feb 11 ’25, another insider, Calvin Sandra, who serves as the SVP, CHIEF ACCOUNTING OFFICER of the company, sold 54,244 shares for $25.00 each. As a result, the insider received 1,356,100 and left with 54,410 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.09.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $5.12. The 50-Day Moving Average of the stock is 20.59%, while the 200-Day Moving Average is calculated to be 71.47%.
Shares Statistics:
A total of 87.03M shares are outstanding, with a floating share count of 85.68M. Insiders hold about 1.55% of the company’s shares, while institutions hold 111.15% stake in the company.
